%0 Journal Article
%T Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
%A Dejager S
%A Schweizer A
%A Foley JE
%J Vascular Health and Risk Management
%D 2012
%I 
%R http://dx.doi.org/10.2147/VHRM.S31758
%X ence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus Review (3456) Total Article Views Authors: Dejager S, Schweizer A, Foley JE Published Date May 2012 Volume 2012:8 Pages 339 - 348 DOI: http://dx.doi.org/10.2147/VHRM.S31758 Received: 14 March 2012 Accepted: 10 April 2012 Published: 18 May 2012 Sylvie Dejager,1 Anja Schweizer,2 James E Foley3 1Novartis Pharma SAS, Rueil Malmaison, France; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Abstract: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years¡¯ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate. In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, this review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease.
%K vildagliptin
%K type 2 diabetes
%K dipeptidyl peptidase-4 inhibitors
%K monotherapy
%K elderly
%U https://www.dovepress.com/evidence-to-support-the-use-of-vildagliptin-monotherapy-in-the-treatme-peer-reviewed-article-VHRM